Evaluation of IFN-γ effects on apoptosis and gene expression in neuroblastoma-Preclinical studies

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 10, 2006, Pages 1000-1010

  Tekautz, Tanya M ^a   Zhu, Kejin ^a   Grenet, Jose ^a   Kaushal, Deepak ^a   Kidd, Vincent J ^a   Lahti, Jill M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis; Caspase 8; Interferon ; Microarray; MYCN; Neuroblastoma

Indexed keywords

CASPASE 8; DOXORUBICIN; GAMMA INTERFERON;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; INTERFERON-GAMMA; METHYLATION; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 33749349821     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.06.014     Document Type: Article

References (66)

1. Engels I.H., Stepczynska A., Stroh C., Lauber K., Berg C., Schwenzer R., Wajant H., Janicke R.U., Porter A.G., Belka C., Gregor M., Schulze-Osthoff K., and Wesselborg S. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 19 (2000) 4563-4573
2. Tekautz T., Teitz T., Lahti J.M., and Kidd V.J. Pro-apoptotic gene silencing via methylation in human tumors. In: El-Deiry W. (Ed). Death receptors in human cancer (2004), Humana Press, Totowa 207-229
3. Reed J.C., and Tomaselli K.J. Drug discovery opportunities from apoptosis research. Curr. Opin. Biotechnol. 11 (2000) 586-592
4. Kaufmann S.H., and Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22 (2003) 7414-7430
5. Earnshaw W.C., Martins L.M., and Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68 (1999) 383-424
6. Kidd V.J. Proteolytic activities that mediate apoptosis. Annu. Rev. Physiol. 60 (1998) 533-573
7. Kidd V.J., Lahti J.M., and Teitz T. Proteolytic regulation of apoptosis. Semin. Cell Dev. Biol. 11 (2000) 191-201
8. Pingoud-Meier C., Lang D., Janss A.J., Rorke L.B., Phillips P.C., Shalaby T., and Grotzer M.A. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer Res. 9 (2003) 6401-6409
9. Zuzak T.J., Steinhoff D.F., Sutton L.N., Phillips P.C., Eggert A., and Grotzer M.A. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur. J. Cancer 38 (2002) 83-91
10. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., Zangemeister-Witte U., and Staehl R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10 (2003) 356-364
11. Shivapurkar N., Reddy J., Matta H., Sathyanarayana U.G., Huang C.X., Toyooka S., Minna J.D., Chaudhary P.M., and Gazdar A.F. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21 (2002) 8510-8514
12. Harada K., Toyooka S., Shivapurkar N., Maitra A., Reddy J.L., Matta H., Miyajima K., Timmons C.F., Tomlison G.E., Mastrangelo D., Hay R.J., Chaudhary P.M., and Gazdar A.F. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 62 (2002) 5897-5901
13. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., and Kidd V.J. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6 (2000) 529-535
14. Fulda S., Kufer M.U., Meyer E., Van Valen F., Dockhorn-Dworniczak B., and Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20 (2001) 5865-5877
15. Eggert A., Grotzer M.A., Zuzak T.J., Weiwrodt B.R., Ho R., Ikegaki N., and Brodeur G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 61 (2001) 1314-1319
16. Christman J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21 (2002) 5483-5495
17. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., and Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
18. Eden A., Gaudet F., and Jaenisch R. Response to comment on chromosomal instability and tumors promoted by DNA hypomethylation and induction of tumors in mice by genomic hypomethylation. Science 302 (2003) 1153
19. Yang A.S., Estecio M.R., Garcia-Manero G., Kantarjian H.M., and Issa J.P. Comment on chromosomal instability and tumors promoted by DNA hypomethylation and Induction of tumors in mice by genomic hypomethylation. Science 302 (2003) 1153
20. Fulda S., and Debatin K.M. IFN-gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21 (2002) 2295-2308
21. Lutz W., Fulda S., Jeremias I., Debatin K.M., and Schwab M. MycN and IFN-gamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 17 (1998) 339-346
22. Yang X., Merchant M.S., Romero M.E., Tsokos M., Wexler L.H., Kontny U., Mackall C.L., and Thiele C.J. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63 (2003) 1122-1129
23. Yang X., and Thiele C.J. Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett. 197 (2003) 137-143
24. Casciano I., De Ambrosis A., Croce M., Pagnan G., Di Vinci A., Allemanni G., Banelli B., Ponzoni M., Romani M., and Ferrini S. Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon sensitive response element (ISRE). Cell Death Differ. 11 (2004) 131-134
25. Kim S., Kang J., Evers B.M., and Chung D.H. Interferon-gamma induces caspase-8 in neuroblastoma without affecting methylation of the caspase-8 promoter. J. Pediatr. Surg. 39 (2004) 509-515
26. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
27. Platanias L.C., and Fish E.N. Signaling pathways activated by interferons. Exp. Hematol. 27 (1999) 1583-1592
28. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997) 749-795
29. Easton J., Wei T., Lahti J.M., and Kidd V.J. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 58 (1998) 2624-2632
30. Scaffidi C., Medema J.P., Krammer P.H., and Peter M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272 (1997) 26953-26958
31. Kaushal D., and Naeve C.W. An overview of spotfire for gene-expression studies, Chapter 7. In: Baxevanis A.D., Davison D.B., Roderic D.M., Page G.A., Petsko L.D., and Stein G.D. (Eds). Current Protocols in Bioformatics (2004), Wiley Interscience
32. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., and Speed T.P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30 (2002) e15
33. Pavan L., Tarrade A., Hermouet A., Delouis C., Titeux M., Vidaud M., Therond P., Evani-Brion D., and Fournier. Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARγ in cell invasion process T. Carcinogenesis 24 (2002) 1325-1336
34. Yanai Y., Micallef M.J., Yamamoto S., Yamamoto K., Yamauchi H., Ikegami H., and Kurimoto M. Expression profiling of tumor necrosis factor alpha-induced apoptosis-associated genes in human solid tumors. Anticancer Res. 23 (2003) 2339-2348
35. Santangelo C., Scipioni A., Marselli L., Marchetti P., and Dotta F. Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur. J. Endo. 152 (2005) 289-482
36. Husson H., Carideo E.G., Neuberg D., Schultze J., Munoz O., Marks P.W., Donovan J.W., Chillemi A.C., O'Connell P., and Freedman A.S. Gene expression profiling of follicular lymphoma and normal germinal center B cell using cDNA arrays. Blood 99 (2002) 282-289
37. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
38. Fulda S., and Debatin K.-M. 5-Aza-2'-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25 (2006) 5125-5133
39. Parham D. Pediatric Neoplasia: Morphology and Biology. In: Parham D. (Ed). Neuroblastoma and Related Tumors. 1 ed. (1996), Lippincott-Raven, Philadelphia 105-152
40. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma Nat. Nat. Rev., Cancer 3 (2003) 203-216
41. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., and Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341 (1999) 1165-1173
42. Bowman L.C., Hancock M., Santana V., Hayes F., Kun L., Parham D., Furman W., Rao V., Green A., and Crist W. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988. J. Clin. Oncol. 9 (1991) 1599-1608
43. Ramana C.V., Chatterjee-Kishore M., Nguyen H., and Stark G.R. Complex roles of Stat1 in regulating gene expression. Oncogene 19 (2000) 2619-2627
44. Ihle J.N. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 13 (2001) 211-217
45. Darnell Jr. J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
46. Kim S., Hu W., Thomas R.P., Evers B.M., and Chung D.H. Interferon-γ induces caspase-8 in neuroblastoma cells: death receptor mediated apoptosis is dependent on caspase-8 and concomitant prevention of NF-κB activation. Proc. AACR 43 (2002) 705
47. Banelli B., Casciano I., Croce M., Di Vinci A., Gelvi I., Pagnan G., Brignole C., Allemanni G., Ferrini S., Ponzoni M., and Romani M. Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat. Med. 5 (2002) 29-35
48. Merchant M.S., Yang X., Melchionda F., Romero M., Klein R., Thiele C.J., Tsokos M., Kontny H.U., and Mackall C.L. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res. 22 (2004) 8349-8356
49. Thomas M., Finnegan C.F., Rogers K.M., Purcell J.W., Trimble A., Johnson P.G., and Boland M.P. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 22 (2004) 8357-8364
50. Perkowski S., Sun J., Singhal S., Santiago J., Leikauf G.D., and Albelda S.M. Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am. J. Respir. Cell Mol. Biol. 28 (2003) 682-696
51. Varela N., Munoz-Pinedo C., Ruiz-Ruiz C., Robledo G., Pedroso M., and Lopez-Rivas A. Interferon-gamma sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J. Biol. Chem. 276 (2001) 17779-17787
52. Ruiz-Ruiz C., Muñoz-Pinedo C., and López-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 60 (2000) 5673-5680
53. Evan A., Main E., Zier K., Ikegaki N., Tartaglione M., Kennett R., and Lampson L. The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. Cancer 64 (1989) 1383-1387
54. Mahmoud H.H., Pui C.H., Kennedy W., Jaffe H.S., Crist W.M., and Murphy S.B. Phase I study of recombinant human interferon gamma in children with relapsed acute leukemia. Leukemia 6 (1992) 1181-1184
55. Kurzrock R., Quesada J.R., Rosenblum M.G., Sherwin S.A., and Gutterman J.U. Phase I study of i.v. administered recombinant gamma interferon in cancer patients. Cancer Treat. Rep. 70 (1986) 1357-1364
56. Kurzrock R., Rosenblum M.G., Sherwin S.A., Rios A., Talpaz M., Quesada J.R., and Gutterman J.U. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 45 (1985) 2866-2872
57. Foon K.A., Sherwin S.A., Abrams P.G., Stevenson H.C., Holmes P., Maluish A.E., Oldham R.K., and Herberman R.B. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol. Immunother. 20 (1985) 193-197
58. Rinehart J.J., Malspeis L., Young D., and Neidhart J.A. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J. Biol. Response Modif. 5 (1986) 300-308
59. Geller J., Petak I., Szucs K.S., Nagy K., Tillman D.M., and Houghton J.A. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Clin. Cancer Res. 9 (2003) 6504-6515
60. Halme M., Maasilta P.K., Pyrhonen S.O., and Mattson K.V. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer-a randomised study. Eur. J. Cancer 30A (1994) 11-15
61. Lygidakis N.J., Berberabe A.E., Spentzouris N., Dedemadi G., Kalligas T., Loukas G., and Sotiropoulou V.A. A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology 45 (1998) 2376-2381
62. Pavlidis N., Nicolaides C., Athanassiadis A., Beriatou K., Skarlos D., Giannakakis T., Kosmidis P., Karvounis N., and Fountzilas G. Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study. Oncology 53 (1996) 159-162
63. Schiller J.H., Witt P.L., Storer B., Alberti D., Tombes M.B., Arzoomanian R., Brown R.R., Proctor R.A., Voss S.D., and Spriggs D.R. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 69 (1992) 562-571
64. Schiller J.H., Storer B., Dreicer R., Rosenquist D., Frontiera M., and Carbone P.P. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J. Natl. Cancer Inst. 81 (1989) 1739-1743
65. Schwartzberg L., Petak I., Stewart C.F., Turner P.K., Ashley J., Tillman D.M., Douglas L., Tan M., Billups C., Mihalik R., Weir A., Tauer K., Shope S., and Houghton J.A. Modulation of the Fas signaling pathway by interferon-gamma in therapy of colon cancer: phase I trial and correlative studies of interferon-gamma, 5-fluorouracil and leucovorin. Clin. Cancer Res. 8 (2002) 2488-2498
66. Johnsen J.I., Pettersen I., Ponthan F., Svenbjornsson B., Flaegstad T., and Kogner P. Synergistic induction of apoptosis in neuroblastoma using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int. J. Onocol. 25 (2004) 1849-1857